Gelteq (GELS) Q4 2025 earnings summary

Executive summary

• Focused on developing and commercializing gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, with a white-label business model and five core verticals.

• Prioritized pharmaceutical research and operational improvements in FY2025, with sales activities expected to ramp up in FY2026.

• Completed IPO in October 2024, raising $5.2 million, and secured an equity line of credit for up to $12 million.

• Entered a profit share agreement with Melbourne Health for a new product targeting bowel health.

Financial highlights

• Revenue for FY2025 was AUD $165,645, up from nil in FY2024, as delayed customer orders were fulfilled.

• Net loss after tax for FY2025 was AUD $6,645,453, compared to AUD $3,546,195 in FY2024.

• Research expenses increased 56% to AUD $628,606 due to expanded product testing and new lab facilities.

• Cash and cash equivalents at June 30, 2025 were AUD $344,648, up from AUD $24,522 a year earlier.

• Borrowings increased to AUD $4,217,405, with convertible notes and shareholder loans as primary sources.

• Intangible assets comprised 92.47% of total assets at June 30, 2025.

Outlook and guidance

• FY2026 focus on expanding sales in animal health, nutraceutical, sports, OTC, and pharma verticals.

• Targeting significant revenue growth through existing and new client orders, with about one million units expected from current customers.

• Ongoing clinical trials and regulatory submissions for gel-based drug products, including the 505(b)(2) pathway.

• Plans to hire additional sales managers and increase advertising to support growth.